Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Genotoxicity and Cytotoxicity of Heat-Not-Burn Products vs.
2026-07-31
This study systematically compares the genotoxic and cytotoxic profiles of heat-not-burn products (HnBP) and conventional cigarettes, using both in vivo rat models and in vitro cell assays. Findings indicate HnBP exposure results in significantly lower cytotoxicity and genotoxicity than traditional cigarette smoke, with direct implications for tobacco harm reduction assessment.
-
Morning Endurance Training Drives Superior Adaptations in Mi
2026-07-31
A recent study demonstrates that conducting endurance training during the early active (morning) phase yields faster and more pronounced performance adaptations in mice than identical afternoon training. This work highlights the critical impact of exercise timing on training efficiency and provides new directions for circadian and metabolic research.
-
Stattic in STAT3 Pathway Modulation: Insights from Lymphangi
2026-07-30
Explore how Stattic, a potent STAT3 inhibitor, advances cancer biology and lymphangiogenesis research. This article uncovers unique mechanistic insights and protocol guidance, grounded in cutting-edge evidence.
-
Nilotinib (AMN-107): Reliable Solutions for Kinase Assays
2026-07-30
This article presents scenario-driven guidance for researchers using Nilotinib (AMN-107, SKU A8232) in cell viability, proliferation, and kinase signaling assays. Drawing on validated literature and practical workflow experience, it demonstrates how this selective inhibitor enables reproducible, sensitive experiments in chronic myeloid leukemia and kinase-driven tumor models.
-
TPCA-1 IKK-2 Inhibitor: Precision Workflows for NF-κB Pathwa
2026-07-29
TPCA-1 stands out as a highly selective IKK-2 inhibitor, empowering researchers to dissect NF-κB-driven inflammatory responses with unrivaled specificity. This guide delivers actionable protocols, troubleshooting insights, and contextualizes the latest mechanistic advances for translational inflammation and cell death studies.
-
Mithramycin A in Cancer Biology: Mechanistic Insights and Re
2026-07-29
Explore the advanced mechanism and research protocols of Mithramycin A, a leading anticancer antibiotic. This article offers practical guidance for cancer biology research and highlights how its DNA-binding action uniquely informs oncogene targeting.
-
Tetrahedral DNA Frameworks Enable Efficient Enzymatic DNA Sy
2026-07-28
The reference study introduces tetrahedral DNA nanostructures (TDNs) as a highly ordered interface for enzymatic oligonucleotide synthesis (EOS), overcoming spatial limitations and boosting synthesis efficiency and accuracy. This innovation is vital for applications such as DNA data storage and advanced genetic engineering, offering a scalable alternative to traditional chemical methods.
-
Prenatal Esketamine Impairs Offspring Neurodevelopment via R
2026-07-28
This study demonstrates that prenatal esketamine exposure in rats leads to lasting neurobehavioral deficits in offspring by impairing neuronal proliferation, maturation, and synaptic plasticity. The research leverages S phase DNA synthesis detection to uncover the mechanistic link between reduced neural precursor proliferation and subsequent cognitive and emotional impairments.
-
Letrozole Beyond Protocols: Mechanistic Insights for Transla
2026-07-27
Explore how Letrozole, a potent non-steroidal aromatase inhibitor, transforms breast cancer research by offering mechanistic clarity and experimental precision. This article reveals underexplored dimensions of Letrozole’s molecular action and its translational implications, setting it apart from typical protocol guides.
-
Cy3 NHS ester (non-sulfonated): Technical Guide & Workflow Q
2026-07-27
Cy3 NHS ester (non-sulfonated) enables high-sensitivity fluorescent labeling of amino groups in proteins, peptides, and oligonucleotides for biomedical imaging and quantitative biochemistry. It is optimal where organic co-solvents are acceptable, but not recommended for delicate proteins or fully aqueous labeling workflows.
-
Icariin Targets PDE5A to Enhance Spermatogonial Stem Cell Vi
2026-07-26
The reference study reveals that Icariin, a compound derived from traditional Chinese medicine, directly targets PDE5A to regulate viability, DNA synthesis, and DNA damage in mouse spermatogonial stem cells (SSCs). These findings provide a mechanistic basis for Icariin’s role in male fertility enhancement and inform future protocols for stem cell and reproductive research.
-
Cy3 NHS Ester (Non-Sulfonated): Technical Guide & Workflow Q
2026-07-25
Cy3 NHS ester (non-sulfonated) offers a reliable solution for fluorescent labeling of proteins, peptides, and oligonucleotides where organic co-solvents are compatible. It is not suitable for strictly aqueous workflows or for protocols requiring long-term storage of dye solutions. Researchers should use this product when robust, high-sensitivity labeling is needed and organic solvent tolerance is assured.
-
Breast Cancer’s Reliance on MCL-1’s Canonical Anti-Apoptotic
2026-07-24
This study decisively demonstrates that breast cancer cells depend on MCL-1 primarily through its canonical anti-apoptotic role, not its non-canonical activities. By integrating genetic deletion and targeted pharmacological inhibition, the research establishes a strong mechanistic basis for employing selective MCL-1 inhibitors in breast cancer therapy.
-
Canagliflozin as an SGLT2 Inhibitor: Protocols and Mitochond
2026-07-24
Canagliflozin, a potent SGLT2 inhibitor, is redefining diabetes and kidney disease research by enabling direct interrogation of mitochondrial remodeling and metabolic modulation in vivo. This guide details experimental workflows, evidence-based protocol enhancements, and hands-on troubleshooting tips that leverage APExBIO’s high-purity Canagliflozin for robust, translational outcomes.
-
QNZ (EVP4593) in Translational Neuroinflammation: Beyond NF-
2026-07-23
Explore the advanced scientific landscape of QNZ (EVP4593), a potent NF-κB inhibitor, and uncover its unique translational applications in neuroinflammation and Huntington's disease research. This article provides a mechanistic deep dive and practical guidance not found in previous content.